Latest news with #CGM
Business Wire
8 hours ago
- Business
- Business Wire
Tenovi Expands Access to Glucose Data for Remote Patient Monitoring and Cardiometabolic Programs Through Dexcom Integration
PORTSMOUTH, N.H.--(BUSINESS WIRE)-- Tenovi, a leading provider of remote patient monitoring (RPM) solutions, today announced it now supports Dexcom continuous glucose monitoring (CGM) data directly within its clinician-facing dashboard. This milestone expands Tenovi's ability to support diabetes management programs across healthcare organizations by seamlessly displaying Dexcom CGM data within its existing virtual RPM infrastructure. Through this integration, Tenovi now supports hourly average glucose data visualization for patients using Dexcom real-time CGMs. Healthcare teams using Tenovi's platform can view glucose trends alongside other vital health RPM metrics, without the need to distribute or manage physical inventory of CGM devices. 'Access to glucose insights is vital to managing chronic conditions such as diabetes,' said Iftah Mashav, Chief Growth Officer at Tenovi. 'A Dexcom and Tenovi integration allows our clients to leverage CGM data in virtual care models that are flexible, scalable, and rooted in clinical outcomes.' This expansion supports Tenovi's broader suite of telemetry solutions designed for cardiometabolic populations, an area of growing focus for health plans and employer-sponsored programs. By enabling continuous remote access to essential health data, Tenovi helps organizations improve outcomes, reduce costs, and scale value-based care. Tenovi provides secure data access via the Dexcom API, allowing health systems to onboard patients seamlessly without the burden of physical device logistics. Dexcom data access is now live on the Tenovi platform. Healthcare organizations can begin enrolling eligible patients immediately. To learn more or schedule a demo, visit About Tenovi Tenovi is a data aggregation and automation Healthcare IoT platform that connects medical device manufacturers with remote patient monitoring programs. It provides over 40 remote patient monitoring and remote therapeutic monitoring (RTM) device point solutions that integrate with its proprietary Cellular Gateway, automating the transfer of patient vitals. Tenovi's API-driven fulfillment and automation services enable seamless deployment of remote patient and therapeutic monitoring programs. For more information, visit
Yahoo
2 days ago
- Business
- Yahoo
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years
Key Points DexCom has barely scratched the surface of its niche in the diabetes market. As a result of industry challenges, the stock's valuation has now come down. But from here, the stock looks well-positioned to deliver excellent results. 10 stocks we like better than DexCom › Medical device specialist DexCom (NASDAQ: DXCM) has encountered significant headwinds in the past year. The company's financial results haven't been quite up to the market's standards, and broader market volatility caused by President Donald Trump's trade policies isn't helping either. The stock is down 26% over the trailing-12-month period. Yet even with all these challenges, DexCom could be a terrific performer in the next five years. Here's why. There's plenty of white space ahead DexCom markets continuous glucose monitoring (CGM) systems, which are devices that help track blood sugar levels in patients with diabetes. CGMs have at least two advantages: They make measurements automatically, and they make them as often as every five minutes. Consistently monitoring blood glucose levels helps people with diabetes make better health decisions. That's why CGM devices lead to improved outcomes, including less time spent in hyperglycemia. DexCom has significantly increased its installed base over the years. In 2024, it had over 2.5 million customers worldwide. However, the company remains well-positioned to capitalize on a massive global opportunity. In the U.S., DexCom estimates that there are more than 4.5 million diabetes patients on insulin therapy who aren't on CGM yet despite being eligible for third-party coverage for the technology. And that's just the U.S., one of the more advanced countries in terms of CGM penetration. DexCom has typically targeted patients who use insulin, and third-party payers have been more willing to cover these populations. However, last year, it launched Stelo, an over-the-counter CGM option for diabetes patients who aren't on insulin and for people with prediabetes. This move significantly expanded the company's addressable market. CGM penetration in the U.S. for type 2 diabetes patients not on insulin is about 5%, and for prediabetes patients less than 1%. DexCom's opportunities both within and outside the U.S. are massive. The increased adoption of CGM technology has helped its revenue and earnings grow steadily over the past decade, and this trend is likely to continue. DexCom's shares declined last year due to poor financial results; in the U.S., more patients than the company expected took advantage of rebates, leading to lower-than-expected revenue per customer. However, since there's still plenty of work to be done in the CGM market, DexCom can address that issue as it continues to make even more headway in this field. That will allow its financial results to improve. Are DexCom's shares too expensive? The stock's forward price-to-earnings ratio was recently 41.5, much higher than the healthcare sector's average of 15.8. But that forward P/E is on the low end compared to DexCom's average over the past few years: The medical device specialist has historically had steep valuation metrics, but has delivered market-beating returns anyway. In my view, DexCom can do the same in the next five to 10 years. Investors might also be concerned about DexCom's main competitor in the CGM market, Abbott Laboratories. But these rivals have battled it out for years, and there's more than enough space for both to be successful, given the large worldwide CGM opportunity. Furthermore, DexCom benefits from a network effect, as multiple companies have developed devices for diabetes patients that are compatible with its technology; these include insulin pens and pumps, third-party apps, and the Apple Watch. The more DexCom's installed base increases, the more attractive its ecosystem becomes to device or app developers looking to target a large population of patients. And as these companies launch more technologies compatible with DexCom's CGM devices, they also become more appealing to patients. This dynamic makes it likely that DexCom will remain a leader in CGM well beyond the next five years. In the meantime, the stock could rebound from its poor performance last year, and deliver superior returns through the end of the decade. Do the experts think DexCom is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did DexCom make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,048% vs. just 180% for the S&P — that is beating the market by 867.59%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories and Apple. The Motley Fool recommends DexCom and recommends the following options: long January 2027 $65 calls on DexCom and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy. Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years was originally published by The Motley Fool
The Hindu
3 days ago
- Health
- The Hindu
Children with Type 1 Diabetes in Kozhikode to get free glucose monitoring systems
The District Institute of Education and Training (DIET) will compile details of around 300 children suffering from Type 1 Diabetes in Kozhikode, who will be provided with continuous glucose monitoring (CGM) systems for free by August 15. A life-long disease, Type 1 diabetes is a result of the body's immune system attacking and destroying cells producing insulin, a hormone necessary for regulating blood sugar, in the pancreas. This leads to high levels of glucose in the bloodstream. The scheme to provide CGM systems to such patients is being implemented by the district administration, DIET, and the Type 1 Diabetics Welfare Society. U.K. Abdunnasar, principal, DIET, told The Hindu on Sunday (July 20) that the data collection of around 200 children had been completed. The process is expected to get over by July 30, he added. According to official sources, the plan is to collect at least 1,000 CGM systems with the help of hospitals, organisations such as Lions' Club and Rotary Club, merchants and industrialists and other non-governmental organisations. The CGM systems will be distributed as per existing guidelines. The sources say that the scheme aims to train children suffering from Type 1 diabetes in a healthy lifestyle, create awareness among people about the problems faced by them, and encourage studies and research on the disease. Studies have revealed that the life expectancy of such patients in the country is less compared to their counterparts in developed countries because of a lack of proper care. While in developed countries their average life expectancy is above 70 years, in India it is below 35 years, they say.
The Hindu
16-07-2025
- Business
- The Hindu
How is global shipping trying to decarbonise?
The story so far: Global shipping is on course towards decarbonisation by 2040-50. This represents a huge opportunity for India. Merchant ships largely use Very Low Sulphur Fuel Oil (VLSFO), diesel, and methane gas stored in liquid form as fuel. LNG-powered engines with their higher efficiency of some five percentage points are likely to be a transition fuel before shipping moves to green fuels such as green ammonia, green or e-methanol and biofuels by 2040 and net zero thereon. How are green fuels produced? Green hydrogen is made from the electrolysis of water using renewable power. Shipping will not use hydrogen directly because of issues with storage and transportation of hydrogen, a highly volatile fuel. Green ammonia, made from green hydrogen and nitrogen, is more stable. The government is also encouraging green ammonia production in India since it can substitute LNG imports in making fertilizers. Green methanol is made from green hydrogen and carbon dioxide obtained from industrial sources. What are the preferred fuels? Shipping, however, is generally a conservative industry. New technology adoption is relatively slow. Ammonia engines are a novelty, so shipping is going first for green methanol, which emits some 10% of carbon dioxide, and later green ammonia, which emits no greenhouse gas. However, ammonia use requires extensive processes onboard. Besides a storage tank and tweaks to the engine and fuel handling system, green methanol is almost a drop-in replacement for VLSFO and is stored as liquid in ambient temperature unlike green ammonia or even LNG. Already, more than 360 ships capable of operating on methanol are either in service or in order. Major container shipping companies such as Maersk, CMA, CGM and Evergreen are backing methanol. A 100% sustainable e-methanol as bunker fuel costs $1,950 per tonne (of VLSFO equivalent) in February in Singapore, while VLSFO averaged at $560 per tonne. This pricing discrepancy is primarily caused by the present price of renewable electricity, with every tonne of green e-methanol using 10-11 MWh of power, and the heavy upfront capital cost for electrolyser facilities. Estimates suggest that demand for green methanol would surpass 14 million tonnes by 2028, whereas the projected supply is merely in the order of 11 million tonnes, creating additional price pressures. What is Indian shipping's decarbonisation plans? India has committed to decarbonising its domestic shipping. Plans have been made for supporting domestic container ships using green fuels as well as creating green fuel bunkering points such as at the Tuticorin V.O. Chidambaranar port and Kandla. The government is looking at producing and supplying green fuels to Singapore, which is a fuelling station accounting for nearly one-fourth of all global ship fuelling. Singapore has committed to being a green fuels supplier and would require therefore tens of millions of tonnes of green fuels. Given that India has the land and expertise for solar power, it can aspire to be a major supplier of green fuels to global shipping. How can India do it? Making a marine green fuels production hub has some challenges. Solar panels and electrolysers to make green hydrogen need to be imported. India's solar energy revolution, however, is a model of how sovereign guarantees and policy strategic frameworks can drive the adoption of green fuels. From 2014 to 2025, India's solar capacity grew from 2.82 GW to 105 GW. This achievement was made through the convergence of sovereign guarantees, off-take assurance, and strengthened supply chain support. Sovereign guarantees have emerged as a powerful de-risking mechanism for green methanol investments that can considerably reduce prices. These government-backed assurances can fundamentally transform project economics by enabling access to international capital markets at significantly lower interest rates. Innovative financial instruments are needed for an at to scale green methanol rollout. Production-linked incentive (PLI) schemes for electrolysers can relieve supply chain bottlenecks by territorialising value chains and lessening transportation costs of raw materials. Carbon capture, utilisation, and storage (CCUS) incentives are also essential, as they increase the feasibility of the production of green methanol from sequestered CO2. Further, the government's aggressive push in creating 1.5 GW of local electrolyser manufacturing capacity and growing industrial CO2 sources (from steel and cement industries) positions India strategically to develop integrated green fuel hubs. Multilateral development banks offer financing at rates as low as 4%, as opposed to 11-12% by domestic lenders, and they can be leveraged. How can green fuels help restart Indian shipowning and shipbuilding? The government's move to inject demand-side support for shipbuilders, along with incentives for foreign cooperation, should spur economies of scale and attract global shipbuilders to the country. Partnerships with overseas shipbuilders from South Korea and Japan are being pursued to support India's shipbuilding strength. The strategy is to support new builds and retrofit current ships for green fuel compatibility. India has pledged $10 billion to support the purchase of over 110 ships. Government can provide incentives so 10-20% of these are green fuel-capable, built in Indian shipyards, and are Indian-flagged.
Time of India
15-07-2025
- Health
- Time of India
AI, Modern Tech & the evolving dynamics of Patient Care in India
New Delhi: As healthcare professionals in India increasingly adopt digital tools in clinical practice , advancements such as genomics, AI, and data analytics are transforming patient care—enabling personalized treatments and accelerating timely, effective interventions. While adoption is steadily increasing, it faces significant challenges—including inadequate infrastructure, rising costs, and unresolved data privacy concerns. Delving into this space the inaugural edition of ETHealthworld FutureMed X - The Smart Patient Care Summit convened a panel discussion on Reengineering Patient Care- A Changemakers Perspective. The experts who shared their insights at the session included Prof Anurag Agrawal, Head-Koita Center for Digital Health & Dean - BioSciences and Health Research, Ashoka University, Dr. Raj Shankar Ghosh, Senior Advisor, Environmental Health, Public Health Foundation of India (PHFI), Dr Chandrakant Lahariya Founder -Director, Foundation of People Centric Health System; Leena Menghaney, Lawyer/Consultant, Public Health, Pharmaceuticals & Access; and the discussion was moderated by Vikas Dandekar Editor ETHealthworld, The Economic Times. AI diagnostics drive and the mid way challenges Radiology services in India stands as a frontrunner in AI adoption, where its integration is helping them to cut down time lines of analysing millions of scans, However Prof Agrawal, noted, 'while radiologist have increasingly adopted AI these tools are not yet advanced enough to be fully relied upon for clinical decision-making and the coming age of medical professionals is facing entering a field where technological integration presents both promise and pressure.' Citing examples like Continuous Glucose Monitoring (CGM)--a technology used to track glucose levels in real-time round the clock—Lehariya stressed that such innovations have shown their potential but their adoption is yet to scale up in India and the growing integration of artificial intelligence (AI) in healthcare should prioritise expanding access, reaching underserved communities, and improving outcomes on the ground.' 'We will keep evolving and innovating new things but from the very beginning we should focus on taking those innovations to a broader section of society and unless that is achieved it will be partial success,' Dr Lehariya stressed. 'The advent of AI is steadily making its mark in healthcare. To develop a comprehensive, integrated solution for diverse health challenges, stakeholders must unite their efforts toward the concept of One Health—linking environmental, animal, and human health, Dr Ghosh, said 'Empowering communities to build trust is essential, so AI becomes part of daily life and effectively addresses a range of healthcare issues,' he added. Policy Efforts On the policy front, Menghaney emphasized the introduction of HMIS (Health Management Information System) reflects some potential; the absence of ethical frameworks hinders accountable use of digital tools, and introducing strong data protection provisions is essential to unlock the benefits of digitization in public health decision-making. To counter misinformation Prof Aggarwal suggested that, 'there should be constant level of high-surveillance all the time, creation of trusted voices with continuous release of information to counter various misleading information and myths While India's healthcare system has long been oriented toward treating infectious and acute diseases, the rising prevalence of non-communicable diseases (NCDs) demands a shift in approach. Clinicians and healthcare providers must rethink existing models and adopt innovative strategies to meet this emerging challenge. Dr Lehariya added that, while India's healthcare system has long been oriented toward treating infectious and acute diseases, the rising prevalence of non-communicable diseases (NCDs) demands a shift in approach.
